Compound Summary
Compound Information
pimozide
Compound Name: | pimozide |
Compound CID: | 16362 |
Synonyms: | pimozide 2062-78-4 Orap Opiran Pimozidum More... |
Iupac Name: | 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one |
InChI: | InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34) |
InChIKey: | YVUQSNJEYSNKRX-UHFFFAOYSA-N |
Canonical Smiles: | C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F |
Isomeric Smiles: | C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F |
Molecular Weight: | 461.5 |
Molecular Formula: | C28H29F2N3O |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
pimozide
Molecular Weight: | 461.5 |
Molecular Formula: | C28H29F2N3O |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 4 |
Rotatable Bond Count: | 7 |
Heavy Atom Count: | 34 |
Complexity: | 632 |
Synonyms
pimozide
| pimozide | pimozide |
|---|---|
pimozide |
2062-78-4 |
Orap |
Opiran |
Pimozidum |
Pimozidum INN-Latin |
McN-JR-6238 |
R-6238 |
R 6238 |
R6238 |
UNII-1HIZ4DL86F |
NSC 170984 |
McN-JR 6238 |
3-1-4,4-bis(4-fluorophenyl)butylpiperidin-4-yl-1H-benzimidazol-2-one |
2H-Benzimidazol-2-one, 1-1-4,4-bis(4-fluorophenyl)butyl-4-piperidinyl-1,3-dihydro- |
1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone |
1-1-4,4-Bis(p-fluorophenyl)butyl-4-piperidyl-2-benzimidazolinone |
1HIZ4DL86F |
CHEMBL1423 |
1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine |
1-1-4,4-bis(4-Fluorophenyl)butyl-4-piperidinyl-1,3-dihydro-2H-benzimidazol-2-one |
MLS000028410 |
MLS002702058 |
CHEBI:8212 |
MFCD00055081 |
NSC170984 |
1-{1-4,4-bis(4-fluorophenyl)butylpiperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one |
1-{1-4,4-bis(4-fluorophenyl)butylpiperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one |
2H-Benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro- |
NSC-170984 |
NCGC00015802-08 |
NCGC00015802-18 |
Primozida |
SMR000058385 |
CAS-2062-78-4 |
DSSTox_CID_3474 |
1-(1-(4,4-bis(4-fluorophenyl)butyl)piperidin-4-yl)-1H-benzodimidazol-2(3H)-one |
DSSTox_RID_77042 |
DSSTox_GSID_23474 |
Primozida INN-Spanish |
pimozida |
Primozide |
C28H29F2N3O |
Pimozida INN-Spanish |
1-4,4-Bis(p-fluorophenyl)butyl-4-(2-oxo-1-benzimidazolinyl)piperidine |
CCRIS 9172 |
Orap (TN) |
SR-01000075392 |
EINECS 218-171-7 |
BRN 0729089 |
1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one |
Prestwick_395 |
Pimozide USAN:USP:INN:BAN:JAN |
Spectrum_000445 |
Tocris-0937 |
Opera_ID_1580 |
Prestwick0_000308 |
Prestwick1_000308 |
Prestwick2_000308 |
Prestwick3_000308 |
Spectrum2_001026 |
Spectrum3_001451 |
Spectrum4_000420 |
Spectrum5_001308 |
Lopac-P-1793 |
GTPL90 |
NCIMech_000356 |
P 1793 |
Lopac0_000946 |
SCHEMBL41584 |
BSPBio_000276 |
BSPBio_001439 |
BSPBio_002941 |
KBioGR_000720 |
KBioSS_000925 |
5-24-02-00367 (Beilstein Handbook Reference) |
MLS001077311 |
BIDD:GT0435 |
DivK1c_000386 |
Methyl-(2-m-tolylethyl)amine |
SPECTRUM1501134 |
Pimozide (JP17/USP/INN) |
SPBio_001211 |
SPBio_002495 |
BPBio1_000304 |
SCHEMBL7519553 |
DTXSID8023474 |
BCBcMAP01_000043 |
HMS501D08 |
KBio1_000386 |
KBio2_000925 |
KBio2_003493 |
KBio2_006061 |
KBio3_002441 |
AOB5780 |
NINDS_000386 |
HMS1568N18 |
HMS1791H21 |
HMS1921H19 |
HMS1989H21 |
HMS2089C11 |
HMS2092F09 |
HMS2095N18 |
HMS2231P23 |
HMS3262N14 |
HMS3267E19 |
HMS3370N13 |
HMS3402H21 |
HMS3411J16 |
HMS3675J16 |
HMS3712N18 |
Pharmakon1600-01501134 |
ZINC4175630 |
Tox21_110224 |
Tox21_301586 |
Tox21_500946 |
BDBM50334150 |
CCG-35918 |
CCG-36461 |
CCG-39728 |
NSC757854 |
s4358 |
2-Benzimidazolinone, 1-1-4,4-bis(p-fluorophenyl)butyl-4-piperidyl- |
3-1-4,4-bis(4-fluorophenyl)butyl-4-piperidyl-1H-benzimidazol-2-one |
AKOS024458706 |
Tox21_110224_1 |
DB01100 |
LP00946 |
NSC-757854 |
SDCCGSBI-0050920.P004 |
IDI1_000386 |
SMP1_000241 |
NCGC00015802-01 |
NCGC00015802-02 |
NCGC00015802-03 |
NCGC00015802-04 |
NCGC00015802-05 |
NCGC00015802-06 |
NCGC00015802-07 |
NCGC00015802-09 |
NCGC00015802-10 |
NCGC00015802-11 |
NCGC00015802-12 |
NCGC00015802-13 |
NCGC00015802-14 |
NCGC00015802-15 |
NCGC00015802-16 |
NCGC00015802-26 |
NCGC00015802-29 |
NCGC00016601-01 |
NCGC00022282-03 |
NCGC00024888-01 |
NCGC00024888-02 |
NCGC00024888-03 |
NCGC00024888-04 |
NCGC00024888-05 |
NCGC00024888-06 |
NCGC00024888-07 |
NCGC00255294-01 |
NCGC00261631-01 |
AS-13916 |
HY-12987 |
M828 |
SBI-0050920.P003 |
AB00052215 |
CS-0012921 |
EU-0100946 |
FT-0673903 |
R-623 |
SW196639-3 |
C07566 |
D00560 |
AB00052215-06 |
AB00052215_07 |
AB00052215_08 |
062P784 |
117210-EP2272537A2 |
117210-EP2275420A1 |
117210-EP2295061A1 |
117210-EP2298776A1 |
L000494 |
Q144085 |
WLN: T56 BMVNJ D- DT6NTJ A3YR DF&R DF |
J-013477 |
SR-01000075392-1 |
SR-01000075392-3 |
SR-01000075392-4 |
SR-01000075392-6 |
BRD-K01292756-001-06-0 |
BRD-K01292756-001-13-6 |
Pimozide, European Pharmacopoeia (EP) Reference Standard |
Z241910386 |
2-Benzimidazolinone,4-bis(p-fluorophenyl)butyl-4-piperidyl- |
N-benzyl-N-(3-isobutoxy-2-(pyrrolidin-1-yl)propyl)benzenamine |
Pimozide, United States Pharmacopeia (USP) Reference Standard |
1-1-4,4-Bis(p-flurophenyl)butyl-4-piperidyl-2-benzimidazolinone |
1-(1-(4,4-bis(4-fluorophenyl)butyl)piperidin-4-yl)-1,3-dihydro-2H-benzodimidazol-2-one |
1-{1-4,4-bis-(4-fluoro-phenyl)-butyl-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one |
2H-Benzimidazol-2-one,4-bis(4-fluorophenyl)butyl-4-piperidinyl-1,3-dihydro- |
1-{1-4,4-Bis-(4-fluoro-phenyl)-butyl-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one(Pimozide) |
Pimozide (1-1-4,4-Bis(4-fluorophenyl)butyl-4-piperidinyl-1,3-dihydro-2H-benzimidaol-2-one) |
PIMOZIDE1-{1-4,4-BIS-(4-FLUORO-PHENYL)-BUTYL-PIPERIDIN-4-YL}-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONE |
Experimental Data
pimozide
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 100 | umol/L | 15.16 | 17.84 | 17.73 | S | N2 | 33008901 | Active | ||||
| Caenorhabditis elegans | 10 | umol/L | 16.58 | 15.86 | -4.343 | NS | N2 | 33008901 | Inactive | ||||
| Drosophila melanogaster | 20 | umol/L | 46.24 | 48.62 | 5.149 | NS | FEMALES | 33008901 | Inactive | ||||
| Drosophila melanogaster | 200 | umol/L | 46.64 | 43.85 | -5.975 | NS | MALES | 33008901 | Inactive | ||||
| Caenorhabditis elegans | 33 | umol/L | -32 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
pimozide
Statistics Data
pimozide
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 17.73 | 2 | 3 | |
| Drosophila melanogaster | 5.149 | 1 | 2 |
Statistics Data Visualization
pimozide
